Top Markets
#1 Songbird Songbird +9.45%
#2 Prom Prom +4.62%
#3 pipedog pipedog +4.04%
#4 TENDIES TENDIES +3.18%
#5 BORA BORA +3.18%
#6 Bitway Bitway +2.76%
#7 PulseX PulseX +2.66%
#8 Wrapped Pulse Wrapped Pulse +2.65%
#9 The Grays Currency The Grays Currency +2.46%
#10 o1.exchange o1.exchange +2.37%
Coin of the day
Songbird Songbird
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Novogene Co., Ltd. Novogene Co., Ltd.

Novogene Co., Ltd.

688315
Kedudukan dalam Saham #9857
Novogene Co., Ltd. is a global provider of comprehensive genomic services and... Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
Harga Saham
$2.25
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$936.66M
Perubahan (1 hari)
-3.18%
Perubahan (1 tahun)
3.07%
Negara
CN
Perdagangan Novogene Co., Ltd. (688315)

Kategori

Healthcare
Nisbah P/E bagi Novogene Co., Ltd. (688315)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Novogene Co., Ltd., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Novogene Co., Ltd. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.